Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

MYC rearrangement + BCL2 rearrangement

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

›

MYC rearrangement + BCL2 rearrangement	Diffuse Large B Cell Lymphoma	MYC rearrangement + BCL2 rearrangement	Diffuse Large B Cell Lymphoma	lisocabtagene maraleucel Sensitive: A2 - Guideline lisocabtagene maraleucel Sensitive : A2	lisocabtagene maraleucel Sensitive: A2 - Guideline lisocabtagene maraleucel Sensitive : A2
MYC rearrangement + BCL2 rearrangement	Diffuse Large B Cell Lymphoma	MYC rearrangement + BCL2 rearrangement	Diffuse Large B Cell Lymphoma	lenalidomide Sensitive: B - Late Trials lenalidomide Sensitive : B	lenalidomide Sensitive: B - Late Trials lenalidomide Sensitive : B
MYC rearrangement + BCL2 rearrangement	Diffuse Large B Cell Lymphoma	MYC rearrangement + BCL2 rearrangement	Diffuse Large B Cell Lymphoma	cytarabine + methotrexate Resistant: C3 – Early Trials cytarabine + methotrexate Resistant : C3	cytarabine + methotrexate Resistant: C3 – Early Trials cytarabine + methotrexate Resistant : C3
MYC rearrangement + BCL2 rearrangement	Diffuse Large B Cell Lymphoma	MYC rearrangement + BCL2 rearrangement	Diffuse Large B Cell Lymphoma	rituximab Resistant: C3 – Early Trials rituximab Resistant : C3	rituximab Resistant: C3 – Early Trials rituximab Resistant : C3
MYC rearrangement + BCL2 rearrangement	Lymphoma	MYC rearrangement + BCL2 rearrangement	Lymphoma	lisocabtagene maraleucel Sensitive: C3 – Early Trials lisocabtagene maraleucel Sensitive : C3	lisocabtagene maraleucel Sensitive: C3 – Early Trials lisocabtagene maraleucel Sensitive : C3
MYC rearrangement + BCL2 rearrangement	Non-Hodgkin’s Lymphoma	MYC rearrangement + BCL2 rearrangement	Non-Hodgkin’s Lymphoma	ibrutinib Sensitive: C3 – Early Trials ibrutinib Sensitive : C3	ibrutinib Sensitive: C3 – Early Trials ibrutinib Sensitive : C3
MYC rearrangement + BCL2 rearrangement	Follicular Lymphoma	MYC rearrangement + BCL2 rearrangement	Follicular Lymphoma	Sensitive: C3 – Early Trials Sensitive : C3	Sensitive: C3 – Early Trials Sensitive : C3
MYC rearrangement + BCL2 rearrangement	Follicular Lymphoma	MYC rearrangement + BCL2 rearrangement	Follicular Lymphoma	Sensitive: C3 – Early Trials Sensitive : C3	Sensitive: C3 – Early Trials Sensitive : C3
MYC rearrangement + BCL2 rearrangement	Diffuse Large B Cell Lymphoma	MYC rearrangement + BCL2 rearrangement	Diffuse Large B Cell Lymphoma	lenalidomide + zanubrutinib Sensitive: C3 – Early Trials lenalidomide + zanubrutinib Sensitive : C3	lenalidomide + zanubrutinib Sensitive: C3 – Early Trials lenalidomide + zanubrutinib Sensitive : C3
MYC rearrangement + BCL2 rearrangement	Diffuse Large B Cell Lymphoma	MYC rearrangement + BCL2 rearrangement	Diffuse Large B Cell Lymphoma	loncastuximab tesirine-lpyl Sensitive: C3 – Early Trials loncastuximab tesirine-lpyl Sensitive : C3	loncastuximab tesirine-lpyl Sensitive: C3 – Early Trials loncastuximab tesirine-lpyl Sensitive : C3
MYC rearrangement + BCL2 rearrangement	Diffuse Large B Cell Lymphoma	MYC rearrangement + BCL2 rearrangement	Diffuse Large B Cell Lymphoma	Sensitive: C3 – Early Trials Sensitive : C3	Sensitive: C3 – Early Trials Sensitive : C3
MYC rearrangement + BCL2 rearrangement	Lymphoma	MYC rearrangement + BCL2 rearrangement	Lymphoma	AR160 Sensitive: C3 – Early Trials AR160 Sensitive : C3	AR160 Sensitive: C3 – Early Trials AR160 Sensitive : C3